OpenCharities

This text was generated using OCR and may contain errors. Check the original PDF to see the document submitted to the regulator.

2025-12-31-accounts

Charity registration number: 1184472

International Cardiomyopathy Network (ICoN)

Annual Report and Financial Statements

for the Year Ended 31 December 2025

Streets (West Sussex) Limited Wiston House 1 Wiston Avenue Worthing West Sussex BN14 7QL

International Cardiomyopathy Network (ICoN)

Contents

Reference and Administrative Details 1
Trustees' Report 2 to 8
Independent Examiner's Report 9
Statement of Financial Activities 10
Balance Sheet 11
Notes to the Financial Statements 12 to 18

International Cardiomyopathy Network (ICoN)

Reference and Administrative Details

Chairman Prof Perry Elliott Charity Registration Number 1184472 Registered Office C/O Cardiomyopathy UK 75a Woodside Road Amersham Buckinghamshire HP6 6AA Independent Examiner Streets (West Sussex) Limited Wiston House 1 Wiston Avenue Worthing West Sussex BN14 7QL

Page 1

International Cardiomyopathy Network (ICoN)

Trustees' Report

The trustees, present the annual report together with the financial statements and auditors' report of the charity for the year ended 31 December 2025.

Chair's introduction

2025 represented an important period of development for the International Cardiomyopathy Network (ICoN). As an international clinician-led charity, our mission is to improve the diagnosis, treatment and long-term management of cardiomyopathies and inherited cardiovascular diseases worldwide.

Cardiomyopathies affect millions of individuals globally and remain a major cause of heart failure, arrhythmia, transplantation and sudden cardiac death. Despite remarkable scientific advances in genetics, imaging and therapeutics, patients continue to experience significant inequalities in access to diagnosis, specialist care and genetic services. Throughout the year, ICoN focused on addressing these disparities by bringing together clinicians, scientists, geneticists, patient organisations and policymakers to drive practical improvements in care delivery.

One of the organisation's most significant achievements during the year was the completion of major policy work examining access to genetic testing for cardiomyopathy across Europe. The outputs of this programme have established ICoN as a respected voice in cardiovascular genetics policy and implementation science.

The Trustees are grateful to all contributors, supporters and collaborators who have helped advance the organisation's mission.

Professor Perry Elliott

Chairman of Trustees

Objectives and activities

Public benefit

The objects of the charity as set out in its governing document are;

(1) To advance the education of healthcare professionals on the subject of cardiomyopathy and related diseases of the heart muscle through the provision of educational learning opportunities and other methods that trustees see fit so as to improve the detection and treatment of such diseases for the public benefit.

(2) To improve the health of people affected by cardiomyopathy and related diseases of the heart muscle through the promotion and facilitation of research for the public benefit in all aspects of cardiomyopathy and related diseases of the heart muscle by providing networking opportunities for researchers, support and advice to researchers and other means trustees see fit.

(3) To advance the education of healthcare professionals worldwide through the dissemination of the results of research into cardiomyopathy and related diseases of the heart muscle.

(4) To improve the health of people affected by cardiomyopathy and diseases of the heart muscle worldwide through the creation, monitoring and development of relevant guidance on the treatment of such diseases. (5) To improve the health of people affected by cardiomyopathy worldwide through collaboration with relevant stakeholders in advocating for improved access to treatment for people affected by such diseases.

(6) To increase awareness of cardiomyopathy and related disorders among the general public and the support and information available to people with cardiomyopathy and related conditions.

The trustees confirm that they have complied with the requirements of section 17 of the Charities Act 2011 to have due regard to the public benefit guidance published by the Charity Commission for England and Wales.

Page 2

International Cardiomyopathy Network (ICoN)

Trustees' Report

Strategic review

Cardiomyopathies affect approximately one in every 200 to 300 people and are a major contributor to heart failure, implantable cardioverter defibrillator implantation, heart transplantation and sudden cardiac death. Yet significant challenges remain:

Scientific progress continues to accelerate, but implementation within healthcare systems remains uneven. ICoN's strategy is focused on ensuring that advances in genomics, imaging and precision medicine are translated into practical benefits for patients.

Strategic Priorities

During 2025, the Board focused on five areas:

Page 3

International Cardiomyopathy Network (ICoN)

Trustees' Report

Achievements and performance

In 2025,Trustees were able to make further progress in line with the charity's objectives.

Genetic Testing Policy Programme

The principal area of activity during 2025 was the completion of an ambitious programme examining the implementation of genetic testing in cardiomyopathy care. Working with the Health Policy Partnership, international experts and patient representatives, ICoN developed two major publications:

  1. “Genetic Testing in Cardiomyopathy: Ensuring Our Future Health Systems Leave No Family Behind”

  2. “Genetic Testing in Cardiomyopathy: Recommendations for the European Union”

The reports identified substantial barriers to implementation across Europe, including variation in reimbursement models, workforce capacity and access to specialist cardiogenetic services. The publications provide practical recommendations designed to support policymakers, healthcare providers and patient organisations.

Policy Engagement

ICoN actively engaged with European policy discussions relating to cardiovascular health and inherited diseases.

The organisation advocated for:

  1. Inclusion of inherited cardiovascular disease within prevention programmes.

  2. Wider implementation of family screening.

  3. Improved access to genetic counselling.

  4. Better workforce training.

  5. Enhanced integration of precision medicine within healthcare systems.

International Collaboration

The organisation continued to expand its network of international collaborators. A major milestone was support from the World Heart Federation for ICoN's genetic testing programme. The Federation recognised the importance of improving access to genetic testing globally and formally endorsed the initiative. The relationship has created opportunities for future projects examining inherited cardiovascular diseases at an international level.

Research Support

ICoN maintained its commitment to promoting research-ready healthcare ecosystems.

The organisation advocated:

Page 4

International Cardiomyopathy Network (ICoN)

Trustees' Report

Communication and Knowledge Dissemination

A substantial effort was devoted to the dissemination of ICoN's policy outputs and thought leadership. The charity enhanced awareness of cardiomyopathy issues through website content, stakeholder engagement and publication of reports designed to inform healthcare leaders and policy makers.

Strategic Growth and Sustainability

Several strategic initiatives were undertaken, including development of partnership strategies, preparation of funding proposals, exploration of corporate engagement opportunities, expansion of stakeholder networks and development of long-term operational planning. The Board worked to establish a more sustainable funding model that would support future activities while preserving scientific independence and charitable objectives. These efforts included review of sponsorship models, philanthropic opportunities and strategic partnerships aligned with the charity's mission.

Financial review

Trustees are pleased to report that the charity remains financially secure. During the year, expenses have been kept at a minimum. Income for the year was £140,157, almost entirely restricted grant funding of £140,000 from funders for the genetic testing project. Expenditure was £131,889, predominantly spent on the genetic testing project. Net income of £8,268 increased total funds to £41,527 at 31 December 2025, of which £41,330 is restricted. These restricted funds will be used during 2026 to support the dissemination and implementation of the project's recommendations on genetic testing, as set out in the plans for future periods below. Unrestricted funds were £197.

Policy on reserves

The trustees have examined the charity's requirements for reserves in light of the main risks to the organisation. The trustees actively review the major risks that the charity faces on a regular basis and, combined, with the annual review of the controls over key financial systems, will provide sufficient resources in the event of adverse conditions. The trustees have also examined other operational and business risks faced by the charity and confirm that they have established systems to mitigate the significant risks. The trustees have agreed that the charity should aim to have unrestricted reserves roughly equivalent to three months' running costs in order to guard against risk, unexpected fluctuations in income or other emergencies as well as meeting any obligations in the event of closure. At 31 December 2025 the charity has a small unrestricted reserve fund but is sufficient to cover the small running costs without premises or staff costs to consider.

Page 5

International Cardiomyopathy Network (ICoN)

Trustees' Report

Plans for future periods

Aims and key objectives for future periods

Aims and key objectives for future periods

The Trustees have identified several priorities for the coming period.

Implementation of Policy Recommendations

ICoN will support dissemination and implementation of its recommendations on genetic testing and inherited cardiovascular disease policy.

Development of Workforce Education

The organisation will advance plans for an international educational programme focused on inherited cardiovascular diseases and cardiovascular genetics. This initiative aims to improve workforce capability and prepare future clinical leaders.

Expansion of International Partnerships

ICoN intends to strengthen relationships with professional societies, patient organisations and global health bodies, building on existing collaboration with the World Heart Federation.

Research and Data Infrastructure

The organisation will continue to advocate for better data sharing, international collaboration and research-ready health systems capable of supporting precision cardiovascular medicine.

Organisational Sustainability

Further work will be undertaken to secure sustainable funding and establish infrastructure proportionate to ICoN's growing international role.

Going concern

The charity has reviewed it's financial performance and general reserves position. The charity has adequate financial resources and is able to manage it's business risks. The charity's planning process has taken into consideration the current economic climate and its potential impact on the various sources of income and planned expenditure.

Taking into account all factors the charity has reasonable expectation that it has adequate resources to continue in operational existence for the foreseeable future and believe that there are no material uncertainties that call into the charity's ability to continue in operation.

Trustees and officers

The trustees and officers serving during the year and since the year end were as follows:

Page 6

International Cardiomyopathy Network (ICoN)

Trustees' Report

Trustees:

Dr Juan Ramon Gimeno Blanes Prof Lucie Carrier Prof Perry Elliott Prof Eloisa Arbustini Prof Iacopo Olivotto Prof Juan Pablo Kaski Prof Jolanda Ven Der Velden Prof Ales Linhart Dr Aristides Anastasakis Prof Guiseppe Limongelli

Chairman:

Prof Perry Elliott

Structure, governance and management

Nature of governing document

The charity is registered as a charitable incorporated organisation (CIO). The members of the CIO are its charity trustees. The only persons eligible to be members of the CIO are its charity trustees. Membership of the CIO cannot be transferred to anyone else. Any member and charity trustee who ceases to be a charity trustee automatically ceases to be a member of the CIO.

Apart from the first charity trustees, every trustee must be appointed for a term of 3 years by a resolution passed at a properly convened meeting of the charity trustees. In selecting individuals for appointment as charity trustees, the charity trustees must have regard to the skills, knowledge and experience needed for the effective administration of the CIO.

Recruitment and appointment of trustees

Trustees are appointed in accordance with the governing document. The Board seeks to maintain an appropriate balance of expertise across clinical medicine, cardiovascular science, healthcare policy, finance, governance and patient engagement. Prospective trustees are selected on the basis of their skills, experience, personal qualities and commitment to the charitable objectives of ICoN.

Induction and training of trustees

New trustees are made familiar with the charity's vision, operation and goals by dialogue with existing personnel and provision of literature pertaining to charity activity. All trustees are already familiar with the practical work of the charity. New trustees are encouraged to attend all management committee meetings. Short training sessions (if required) to familiarise new trustees with the charity and the context within which it operates are provided internally. Trustees are encouraged to identify any training needs and are provided with relevant governance updates and guidance where appropriate.

Page 7

International Cardiomyopathy Network (ICoN)

Trustees' Report

Organisational structure

The board of trustees is responsible for the overall management and control of the charity. The trustees meet at least quarterly, with additional meetings as required, to set strategic priorities, review programme delivery, monitor financial performance, assess risks, review governance arrangements and approve major initiatives and partnerships. The organisation operates in the UK from premises in Amersham.

Key strategic and administrative decisions are made by agreement of the trustees. Day to day operational activities may be delegated to officers, advisors, project partners or working groups, but responsibility for strategic oversight remains with the trustees. Day to day management of the charity is supported by Joel Rose, the Chief Executive of Cardiomyopathy UK.

Relationships with related parties

Cardiomyopathy UK (registered charity no. 1164263) provided governance, administrative, fundraising and accountancy support to ICoN during the year for which it was paid £30,000. Prof. Perry Elliott is the President of Cardiomyopathy UK. Both organisations share the goal of advancing the care and treatment of people affected by cardiomyopathy.

Statement of trustees' responsibilities

The trustees are responsible for preparing the trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Charity SORP requires the trustees to prepare financial statements for each financial year. The trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charity and of the incoming resources and application of resources, including its income and expenditure, of the charity for that period. In preparing these financial statements, the trustees are required to:

The trustees are responsible for keeping accounting records that disclose with reasonable accuracy at any time the financial position of the charity. They are also responsible for safeguarding the assets of the charity and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

The annual report was approved by the trustees of the charity on 21 October 2026 and signed on its behalf by:

......................................... Prof Perry Elliott Chairman and trustee

Page 8

International Cardiomyopathy Network (ICoN)

Independent Examiner's Report to the trustees of International Cardiomyopathy Network (ICoN) ('the Company')

I report to the charity trustees on my examination of the accounts of the Charity for the year ended 31 December 2025.

Responsibilities and basis of report

As the charity’s trustees you are responsible for the preparation of the accounts. The charity's trustees consider that an audit is not required for this year under section 144 of the Charities Act 2011 ("the Charities Act") and that an idependent examination is needed.

Having satisfied myself that the charity is not subject to audit and is eligible for independent examination, it is my responsibility to:

Basis of independent examiner's statement

My examination was carried out in accordance with general Directions given by the Charity Commission. An examination includes a review of the accounting records kept by the charity and a comparison of the accounts presented with those records. It also includes consideration of any unusual items or disclosures in the accounts, and seeking explanations from the trustees concerning any such matters. The procedures undertaken do not provide all the evidence that would be required in an audit, and consequently no opinion is given as to whether the accounts present a ‘true and fair’ view and the report is limited to those matters set out in the statement below.

Independent Examiner's statement

In connection with my examination, no material matters have come to my attention which gives me cause to believe that in, any material respect:

• the accounts did not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a "true and fair" view which is not a matter considered as part of an independent examination.

I have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the accounts to be reached.

......................................

Rachel Skells BA BFP FCA ICAEW

Wiston House 1 Wiston Avenue Worthing West Sussex BN14 7QL

26 October 2026

Page 9

International Cardiomyopathy Network (ICoN)

Statement of Financial Activities for the Year Ended 31 December 2025 (Including Income and Expenditure Account and Statement of Total Recognised Gains and Losses)

Note
Income and Endowments from:
Donations and legacies
3
Charitable activities
4
Investment income
5
Total income
Expenditure on:
Raising funds
Charitable activities
6
Total expenditure
Net income
Net movement in funds
Reconciliation of funds
Total funds brought forward
Total funds carried forward
12
Note
Income and Endowments from:
Charitable activities
4
Investment income
5
Total income
Expenditure on:
Raising funds
Charitable activities
6
Total expenditure
Net (expenditure)/income
Net movement in funds
Reconciliation of funds
Total funds brought forward
Total funds carried forward
12
Unrestricted
funds
£
-
-
88
88
-
-
-
88
88
109
197
Unrestricted
funds
£
-
25
25
-
(102)
(102)
(77)
(77)
186
109
Restricted
funds
£
69
140,000
-
140,069
(186)
(131,703)
(131,889)
8,180
8,180
33,150
41,330
Restricted
funds
£
40,000
-
40,000
(176)
(25,817)
(25,993)
14,007
14,007
19,143
33,150
Total
2025
£
69
140,000
88
140,157
(186)
(131,703)
(131,889)
8,268
8,268
33,259
41,527
Total
2024
£
40,000
25
40,025
(176)
(25,919)
(26,095)
13,930
13,930
19,329
33,259

All of the charity's activities derive from continuing operations during the above two periods. The funds breakdown for 2024 is shown in note 12.

The notes on pages 12 to 18 form an integral part of these financial statements.

Page 10

International Cardiomyopathy Network (ICoN)

Balance Sheet as at 31 December 2025

Note
Current assets
Cash at bank and in hand
10
Creditors: Amounts falling due within one year
11
Net assets
Funds of the charity:
Restricted income funds
Restricted funds
Unrestricted income funds
Unrestricted funds
Total funds
12
2025
£
42,186
(659)
41,527
41,330
197
41,527
2024
£
48,871
(15,612)
33,259
33,150
109
33,259

The financial statements on pages 10 to 18 were approved by the trustees, and authorised for issue on 21 October 2026 and signed on their behalf by:

......................................... Prof Perry Elliott Chairman and trustee

The notes on pages 12 to 18 form an integral part of these financial statements. Page 11

International Cardiomyopathy Network (ICoN)

Notes to the Financial Statements for the Year Ended 31 December 2025

1 Charity status

The charity is a Charitable Incorporated Organisation (CIO) and consequently does not have a share capital.

The address of its registered office is: C/O Cardiomyopathy UK 75a Woodside Road Amersham Buckinghamshire HP6 6AA

These financial statements were authorised for issue by the trustees on 21 October 2026.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice (applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)) (issued in October 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

Basis of preparation

International Cardiomyopathy Network (ICoN) meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy notes.

Going concern

The trustees consider that there are no material uncertainties about the charity's ability to continue as a going concern nor any significant areas of uncertainty that affect the carrying value of assets held by the charity. The trustees have a reasonable expectation that the charity will continue in operational existence for the foreseeable future. The financial statements have therefore been prepared on a going concern basis.

Income and endowments

All income is recognised once the charity has entitlement to the income, it is probable that the income will be received and the amount of the income receivable can be measured reliably.

Donations and legacies

Donations are recognised when the charity has been notified in writing of both the amount and settlement date. In the event that a donation is subject to conditions that require a level of performance by the charity before the charity is entitled to the funds, the income is deferred and not recognised until either those conditions are fully met, or the fulfilment of those conditions is wholly within the control of the charity and it is probable that these conditions will be fulfilled in the reporting period.

Page 12

International Cardiomyopathy Network (ICoN)

Notes to the Financial Statements for the Year Ended 31 December 2025

Grants receivable

Grants are recognised when the charity has an entitlement to the funds and any conditions linked to the grants have been met. Where performance conditions are attached to the grant and are yet to be met, the income is recognised as a liability and included on the balance sheet as deferred income to be released.

Deferred income

Deferred income represents amounts received for future periods and is released to incoming resources in the period for which, it has been received. Such income is only deferred when:

Investment income

Investment income comprises interest receivable on bank deposits and is recognised when receivable.

Expenditure

All expenditure is recognised once there is a legal or constructive obligation to that expenditure, it is probable settlement is required and the amount can be measured reliably. All costs are allocated to the applicable expenditure heading that aggregate similar costs to that category. Where costs cannot be directly attributed to particular headings they have been allocated on a basis consistent with the use of resources, with central staff costs allocated on the basis of time spent, and depreciation charges allocated on the portion of the asset’s use. Other support costs are allocated based on the spread of staff costs.

Raising funds

These are costs incurred in attracting voluntary income, the management of investments and those incurred in trading activities that raise funds.

Charitable activities

Charitable expenditure comprises those costs incurred by the charity in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.

Support costs

Support costs include central functions and have been allocated to activity cost categories on a basis consistent with the use of resources, for example, allocating property costs by floor areas, or per capita, staff costs by the time spent and other costs by their usage.

Governance costs

These include the costs attributable to the charity’s compliance with constitutional and statutory requirements, including audit, strategic management and trustees meetings and reimbursed expenses.

Taxation

The charity is considered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definition of a charitable company for UK corporation tax purposes. Accordingly, the charity is potentially exempt from taxation in respect of income or capital gains received within categories covered by Chapter 3 Part 11 of the Corporation Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992, to the extent that such income or gains are applied exclusively to charitable purposes.

Page 13

International Cardiomyopathy Network (ICoN)

Notes to the Financial Statements for the Year Ended 31 December 2025

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the charity does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Fund structure

Unrestricted income funds are general funds that are available for use at the trustees discretion in furtherance of the objectives of the charity.

Restricted income funds are those donated for use in a particular area or for specific purposes, the use of which is restricted to that area or purpose.

Financial instruments

Classification

The charity only has financial assets and liabilties of a kind that qualify as basic financial instruments. Basic financial instruments are initially recognised at transaction value and subsequently measured at their settlement value with the exception of bank loans which are subsequently measured at amortised cost using the effective interest method.

3 Income from donations and legacies

Donations and legacies;
Donations from individuals
Total for 2025
Restricted
funds
£
69
69
Total
funds
£
69
69

4 Income from charitable activities

Project Fund Management
Total for 2025
Total for 2024
Restricted
funds
£
140,000
140,000
40,000
Total
funds
£
140,000
140,000
40,000

Page 14

International Cardiomyopathy Network (ICoN)

Notes to the Financial Statements for the Year Ended 31 December 2025

5 Investment income

Interest receivable and similar income;
Interest receivable on bank deposits
Total for 2025
Total for 2024
Unrestricted
funds
General
£
88
88
25
Total
funds
£
88
88
25

6 Expenditure on charitable activities

Note
Project Fund Management
Governance costs
7
Total for 2025
Total for 2024
Unrestricted
funds
General
£
-
-
-
102
Restricted
funds
£
130,965
738
131,703
25,817
Total
funds
£
130,965
738
131,703
25,919

Total expenditure £

In addition to the expenditure analysed above, there are also governance costs of £738 (2024 - £3,684) which relate directly to charitable activities. See note 7 for further details.

Page 15

International Cardiomyopathy Network (ICoN)

Notes to the Financial Statements for the Year Ended 31 December 2025

7 Analysis of governance and support costs

Governance costs

Other governance costs
Trustees remuneration and expenses
Other governance costs
8
Independent examiner's remuneration
Fees to examiners
The examining of the accounts of the charity
Restricted
funds
£
72
72
Restricted
funds
£
2,867
205
3,072
2025
£
666
Total
2025
£
72
72
Total
2024
£
2,867
205
3,072
2024
£
612

Page 16

International Cardiomyopathy Network (ICoN)

Notes to the Financial Statements for the Year Ended 31 December 2025

9 Taxation

The charity is a registered charity and is therefore exempt from taxation.

10 Cash and cash equivalents

10 Cash and cash equivalents
Cash at bank
11 Creditors: amounts falling due within one year
Trade creditors
Accruals
12 Funds
Balance at 1
January 2025
£
Unrestricted funds
General
109
Restricted funds
33,150
Total funds
33,259
Balance at 1
January 2024
£
Unrestricted funds
General
186
Restricted funds
19,143
Total funds
19,329
Incoming
resources
£
88
140,069
140,157
Incoming
resources
£
25
40,000
40,025
2025
£
42,186
2025
£
-
659
659
Resources
expended
£
-
(131,889)
(131,889)
Resources
expended
£
(102)
(25,993)
(26,095)
2024
£
48,871
2024
£
15,000
612
15,612
Balance at 31
December
2025
£
197
41,330
41,527
Balance at 31
December
2024
£
109
33,150
33,259

Page 17

International Cardiomyopathy Network (ICoN)

Notes to the Financial Statements for the Year Ended 31 December 2025

13 Analysis of net assets between funds

13 Analysis of net assets between funds
Current assets
Current liabilities
Total net assets
Current assets
Current liabilities
Total net assets
Unrestricted
funds
General
£
197
-
197
Unrestricted
funds
General
£
721
(612)
109
Restricted
funds
£
41,989
(659)
41,330
Restricted
funds
£
48,150
(15,000)
33,150
Total funds at
31 December
2025
£
42,186
(659)
41,527
Total funds at
31 December
2024
£
48,871
(15,612)
33,259

14 Related party transactions

There were no related party transactions in the year.

Page 18